,
therapeutic approaches that
target both diseases are needed. Clinical trials are currently underway to explore
Enikeeva, Kadriia,
Rafikova, Guzel,
Sharifyanova, Yuliya,
Mulyukova, Diana,
Vanzin, Alexandr,
Pavlov, Valentin (2024) the effectiveness of treatment, and predict the
therapeutic effect. Under these circumstances, it becomes crucial
BEYLERLI, OZAL,
BEERAKA, NARASIMHA M.,
GAREEV, ILGIZ,
PAVLOV, VALENTIN,
YANG, GUANG,
LIANG, YANCHAO,
ALIEV, GJUMRAKCH (2020) single-stranded RNA molecules that can influence post-transcriptional regulation by controlling
target of TAMs. Finally, we explain how TAMs interfere with currently used anticancer
therapeutics and summarize
Zhu, Weiwei,
Luo, Wu,
Han, Jibo,
Zhang, Qiuyan,
Ji, Lijun,
Samorodov, Aleksandr V.,
Pavlov, Valentin N.,
Zhuang, Zaishou,
Yang, Daona,
Yin, Lina,
Huang, Lijiang,
Liang, Guang (2023) the differential effects and potential
target of Sch B. ALI was induced by intratracheal administration of LPS
their potential as
therapeutic targets for CVD. Special emphasis is placed on miRNAs that regulate T cells
Qian, J.,
Zhuang, F.,
Chen, Y.,
Fan, X.,
Wang, J.,
Wang, Z.,
Wang, Y.,
Xu, M.,
Samorodov, A.V.,
Pavlov, V.N.,
Liang, G. (2022) in DCM and to test the
therapeutic effects of MD2 inhibitor C30 on DCM. Streptozotocin (STZ) was used
CAI, B.,
MA, W.,
WANG, X.,
SUKHAREVA, N.,
HUA, B.,
ZHANG, L.,
LI, X.,
LI, S.,
LIU, S.,
YU, M.,
XU, Y.,
SONG, R.,
XU, B.,
YANG, F.,
HAN, Z.,
DING, F.,
HUANG, Q.,
YU, Y.,
ZHAO, Y.,
WANG, J.,
BAMBA, D.,
PAN, Z.,
YANG, B.,
XU, J.,
ZAGIDULLIN, N.,
LI, F.,
TIAN, Y. (2020) DACH1 silencing-induced cardiomyocyte proliferation. In addition,
targeting a conserved fragment of Lnc
of global death. The purpose of our bioinformatics analysis was to detect viable pathophysiological
targets